<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> is an important cause of poor outcomes in <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> patients </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to assess the effectiveness and safety of nimodipine in the prevention of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in aneurysmal <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We searched Pubmed, OVID, Embase, the Cochrane library, the <z:hpo ids='HP_0001297'>stroke</z:hpo> clinical trial registry, and the National Science and Technology Library database and collected prospective, randomised, controlled clinical trials of the prophylactic use of nimodipine for aneurismal <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>A meta-analysis was performed on the studies that met the criteria for inclusion </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Eight studies met the inclusion criteria, and 1514 patients finished trial observation for the different indicators </plain></SENT>
<SENT sid="5" pm="."><plain>Compared with the placebo group, fully recovered (<z:hpo ids='HP_0000001'>all</z:hpo> cases) patients increased 64% in the nimodipine group (P = 0.0002, OR = 1.64, 95 percent CI 1.26 - 2.13, NNT=-1.048), fully recovered or moderately disabled (<z:hpo ids='HP_0000001'>all</z:hpo> cases) patients increased 79 percent (P = 0.0007, OR = 1.79, 95% CI 1.28 - 2.51, NNT = -5.889), patient <z:hpo ids='HP_0011420'>death</z:hpo> (in <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> cases) decreased 74% (P = 0.008, OR = 0.26, 95% CI 0.09 - 0.71, NNT = 2.298), the incidence of symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> decreased 46% (P &lt; 0.00001, OR = 0.54, 95% CI 0.42 - 0.69, NNT = 1.952), the incidence of delayed neurological function deficits (<z:hpo ids='HP_0000001'>all</z:hpo> cases) decreased 38% (P &lt; 0.0001, OR = 0.62, 95% CI 0.50 - 0.78, NNT = 1.078), the occurrence of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (on CT scan) decreased 58% (P = 0.001, OR = 0.58, 95% CI 0.42 - 0.81, NNT = 3.314), the occurrence of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (in <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> cases) decreased 65% (P = 0.003, OR = 0.35, 95% CI 0.17 - 0.69, NNT = 3.688), the occurrence of <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> (<z:hpo ids='HP_0000001'>all</z:hpo> cases) decreased 48% (P &lt; 0.00001, OR = 0.52, 95% CI 0.41 - 0.66, NNT = 1.196), and the difference in recurrent haemorrhage and adverse reactions between the nimodipine and placebo groups was not statistically significant (nimodipine group versus placebo group, recurrent haemorrhage P = 0.15, OR = 0.75, 95% CI 0.50 - 1.11; adverse reaction P = 0.59, OR = 1.13, 95% CI 0.71 - 1.81) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Compared with placebo, nimodipine can significantly improve clinical outcomes, as assessed by self-formulated standards and Glasgow outcome scores, and it can significantly reduce the occurrence of symptomatic <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and delayed neurological function deficits (<z:hpo ids='HP_0000001'>all</z:hpo> cases), as well as <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e>, although the incidence rate of recurrent haemorrhage and adverse reactions is not significantly reduced by nimodipine </plain></SENT>
</text></document>